Medtronic Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Medtronic wird ein jährliches Gewinn- und Umsatzwachstum von 12.9% bzw. 4.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.4% betragen.
Wichtige Informationen
11.2%
Wachstumsrate der Gewinne
12.0%
EPS-Wachstumsrate
Medical Equipment Gewinnwachstum | 17.6% |
Wachstumsrate der Einnahmen | 4.5% |
Zukünftige Eigenkapitalrendite | 14.9% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 24 Aug 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Medtronic: Still A Buy Before Earnings
Aug 17Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down
Aug 08Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential
Jul 16At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?
Jul 11Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year
Jun 27Medtronic: Why I Disagree With The Crowd
Jun 14Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
May 27Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70
May 26These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well
May 22Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release
May 13Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?
May 0135% Undervalued? Medtronic's Future Looks Very Bright
Apr 12Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now
Mar 27Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth
Mar 11Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69
Mar 11Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
Feb 25Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 22Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
Feb 16A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jan 31Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?
Jan 16Medtronic Stock's Rally Is Set To Continue
Jan 11Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings
Dec 29Medtronic's (NYSE:MDT) Dividend Will Be $0.69
Dec 12Medtronic: The GLP-1 Drug Headwinds Are Overblown
Dec 103.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic
Nov 28Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes
Nov 19Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings
Nov 17Medtronic Faces Potential Decline Despite Financial Strength
Oct 29An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued
Oct 19Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Oct 04Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%
Sep 27Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Sep 18Medtronic: The Tide Is Turning
Aug 24Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Aug 21Medtronic: Dark Clouds Are Clearing - Outperformance Ahead
Aug 14Return Trends At Medtronic (NYSE:MDT) Aren't Appealing
Aug 11Medtronic: Expanding Product Portfolio Without Affecting Dividend Growth
Jul 15Are Medtronic plc (NYSE:MDT) Investors Paying Above The Intrinsic Value?
Jul 09Is Medtronic (NYSE:MDT) A Risky Investment?
Jun 21Medtronic: Weak Forecasts Spoiled Strong Results For The Reporting Quarter
Jun 21Is Medtronic's Dividend In A Good Place?
Jun 14Medtronic (NYSE:MDT) Is Increasing Its Dividend To $0.69
Jun 03Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
4/30/2027 | 36,869 | 6,125 | 7,454 | 8,898 | 21 |
4/30/2026 | 35,163 | 5,700 | 6,771 | 8,545 | 31 |
4/30/2025 | 33,575 | 5,186 | 5,736 | 7,806 | 31 |
7/26/2024 | 32,577 | 3,927 | 5,145 | 6,898 | N/A |
4/26/2024 | 32,364 | 3,676 | 5,200 | 6,787 | N/A |
1/26/2024 | 32,320 | 4,201 | 4,931 | 6,470 | N/A |
10/27/2023 | 31,958 | 4,102 | 4,045 | 5,570 | N/A |
7/28/2023 | 31,558 | 3,620 | 4,444 | 5,831 | N/A |
4/28/2023 | 31,227 | 3,758 | 4,580 | 6,039 | N/A |
1/27/2023 | 30,771 | 4,064 | 4,166 | 5,636 | N/A |
10/28/2022 | 30,806 | 4,321 | 4,822 | 6,290 | N/A |
7/29/2022 | 31,070 | 5,205 | 5,721 | 7,137 | N/A |
4/29/2022 | 31,686 | 5,039 | 5,978 | 7,346 | N/A |
1/28/2022 | 31,785 | 4,914 | 5,678 | 7,034 | N/A |
10/29/2021 | 31,798 | 4,704 | 5,773 | 7,162 | N/A |
7/30/2021 | 31,597 | 3,882 | 5,855 | 7,254 | N/A |
4/30/2021 | 30,117 | 3,606 | 4,885 | 6,240 | N/A |
1/29/2021 | 27,926 | 2,892 | 4,631 | 5,945 | N/A |
10/30/2020 | 27,868 | 3,537 | 4,752 | 5,996 | N/A |
7/31/2020 | 27,927 | 4,412 | 4,756 | 6,002 | N/A |
4/24/2020 | 28,913 | 4,789 | 6,021 | 7,234 | N/A |
1/24/2020 | 31,062 | 5,408 | 6,659 | 7,871 | N/A |
10/25/2019 | 30,891 | 4,762 | 6,298 | 7,519 | N/A |
7/26/2019 | 30,666 | 4,420 | 5,671 | 6,815 | N/A |
4/26/2019 | 30,557 | 4,631 | 5,873 | 7,007 | N/A |
1/25/2019 | 30,555 | 4,826 | 4,867 | 5,958 | N/A |
10/26/2018 | 30,378 | 2,168 | 4,864 | 5,905 | N/A |
7/27/2018 | 29,947 | 3,163 | 4,568 | 5,649 | N/A |
4/27/2018 | 29,953 | 3,104 | N/A | 4,684 | N/A |
1/26/2018 | 29,725 | 2,859 | N/A | 5,419 | N/A |
10/27/2017 | 29,639 | 5,069 | N/A | 5,502 | N/A |
7/28/2017 | 29,934 | 4,115 | N/A | 6,067 | N/A |
4/28/2017 | 29,710 | 4,028 | N/A | 6,880 | N/A |
1/27/2017 | 29,361 | 3,968 | N/A | 6,433 | N/A |
10/28/2016 | 29,012 | 4,242 | N/A | 6,145 | N/A |
7/29/2016 | 28,725 | 3,647 | N/A | 5,952 | N/A |
4/29/2016 | 28,833 | 3,538 | N/A | 5,218 | N/A |
1/29/2016 | 28,435 | 2,434 | N/A | 5,804 | N/A |
10/30/2015 | 25,819 | 2,316 | N/A | 5,774 | N/A |
7/31/2015 | 23,127 | 2,624 | N/A | 5,408 | N/A |
4/24/2015 | 20,261 | 2,675 | N/A | 4,902 | N/A |
1/23/2015 | 17,410 | 3,124 | N/A | 4,318 | N/A |
10/24/2014 | 17,255 | 2,909 | N/A | 4,163 | N/A |
7/25/2014 | 17,083 | 2,983 | N/A | 4,286 | N/A |
4/25/2014 | 16,893 | 3,065 | N/A | 4,959 | N/A |
1/24/2014 | 16,879 | 3,586 | N/A | 4,901 | N/A |
10/25/2013 | 16,743 | 3,812 | N/A | 4,735 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: MDTDas prognostizierte Gewinnwachstum (12.9% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: MDTDie Erträge des Unternehmens (12.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).
Hohe Wachstumserträge: MDTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: MDTDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: MDTDie Einnahmen des Unternehmens (4.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: MDTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.4%).